← Back to Search

Brentuximab Vedotin for T-Cell Lymphoma (BRENTICON-T Trial)

Phase 2
Waitlist Available
Led By Sid Ganguly, MD
Research Sponsored by Siddhartha Ganguly
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from date of randomization until the date of first documented progression or to death due to any cause, whichever comes first, up to 3 years.
Awards & highlights

BRENTICON-T Trial Summary

This trial is studying A-CHP plus brentuximab vedotin as an induction therapy followed by ASCT plus brentuximab vedotin as a consolidation therapy in patients with CD30-positive mature T-cell lymphomas.

Eligible Conditions
  • T-Cell Lymphoma

BRENTICON-T Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to three years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to three years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of participants who experience safety related issues caused by study treatment: CTCAEv5
Secondary outcome measures
Progression Free Survival
The number of adverse events or laboratory abnormalities

Side effects data

From 2020 Phase 4 trial • 60 Patients • NCT01990534
18%
Pyrexia
12%
Peripheral sensory neuropathy
10%
Diarrhoea
10%
Neuropathy peripheral
10%
Neutropenia
8%
Polyneuropathy
8%
Nausea
8%
Anaemia
8%
Upper respiratory tract infection
7%
Arthralgia
7%
Vomiting
7%
Decreased appetite
5%
Hypomagnesaemia
5%
Hypokalaemia
5%
Paraesthesia
5%
Asthenia
5%
Bronchitis
5%
Cough
5%
Alopecia
3%
Oral herpes
3%
Abdominal pain
3%
Back pain
3%
Aspartate aminotransferase increased
3%
Alanine aminotransferase increased
3%
Constipation
3%
Nasopharyngitis
3%
Neutrophil count decreased
3%
Bone pain
3%
Headache
3%
Depression
3%
Thrombocytopenia
3%
Tachycardia
3%
Subcutaneous abscess
3%
Pruritus
3%
Rash
2%
Anaphylactic reaction
2%
Klebsiella infection
2%
Toothache
2%
Ligament sprain
2%
Chills
2%
Fatigue
2%
Blood alkaline phosphatase increased
2%
Lymphocyte count decreased
2%
Oedema
2%
Procedural pain
2%
Gamma-glutamyltransferase increased
2%
Catheter site inflammation
2%
Chest pain
2%
Renal tubular disorder
2%
Malaise
2%
Hyperuricaemia
2%
Influenza
2%
Lymphoedema
2%
Dengue fever
2%
Blood lactate dehydrogenase increased
2%
Facial nerve disorder
2%
Extravasation
2%
General physical health deterioration
2%
Hodgkin's disease
2%
Blood thyroid stimulating hormone increased
2%
Genital haemorrhage
2%
Upper respiratory tract inflammation
2%
Oedema peripheral
2%
Soft tissue inflammation
2%
Temperature regulation disorder
2%
Vaccination site pain
2%
Liver disorder
2%
Breast cellulitis
2%
Platelet count decreased
2%
Weight decreased
2%
Hyperglycaemia
2%
Pain in extremity
2%
Autonomic neuropathy
2%
Dysgeusia
2%
Somnolence
2%
Insomnia
2%
Device related infection
2%
Herpes zoster
2%
Hordeolum
2%
Conjunctivitis
2%
Coxsackie viral infection
2%
Leukocytosis
2%
Leukopenia
2%
Ear pain
2%
Autoimmune thyroiditis
2%
Diplopia
2%
Pseudomonas infection
2%
Sinusitis
2%
Viral infection
2%
Contusion
2%
Haemoglobin decreased
2%
Pneumonia
2%
Device related sepsis
2%
Septic shock
2%
Urinary tract infection
2%
Serum sickness-like reaction
2%
Cerebrovascular accident
2%
Anxiety
2%
Pleural effusion
2%
Vena cava thrombosis
2%
Dyspnoea
2%
Dyspnoea exertional
2%
Nasal congestion
2%
Dermatitis
2%
Dermatitis acneiform
2%
Dermatitis allergic
2%
Dermatitis contact
2%
Erythema
2%
Pruritus generalised
2%
Rash macular
2%
Rash maculo-papular
2%
Rash papular
2%
Rash pruritic
2%
Urticaria
2%
Haematoma
100%
80%
60%
40%
20%
0%
Study treatment Arm
Brentuximab Vedotin 1.8 mg/kg

BRENTICON-T Trial Design

1Treatment groups
Experimental Treatment
Group I: Single ArmExperimental Treatment1 Intervention
Brentuximab vedotin (SGN-35), intravenous infusion, 1.8 milligrams (mg) per kilogram (kg), day one of each twenty- one day cycle with a total of ten cycles planned.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Brentuximab Vedotin
2015
Completed Phase 4
~1070

Find a Location

Who is running the clinical trial?

Siddhartha GangulyLead Sponsor
1 Previous Clinical Trials
101 Total Patients Enrolled
University of Kansas Medical CenterLead Sponsor
463 Previous Clinical Trials
169,270 Total Patients Enrolled
Seagen Inc.Industry Sponsor
208 Previous Clinical Trials
74,228 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has Brentuximab Vedotin been utilized in preceding research initiatives?

"Presently, Brentuximab Vedotin is the subject of 59 ongoing medical trials with 6 in Phase 3. Montvale, New jersey hosts several of these studies while 1851 other sites are hosting their own investigations into this drug's therapeutic potential."

Answered by AI

Is there currently an opportunity to join this medical experiment?

"Affirmative. The clinicaltrials.gov database states that this experiment is actively seeking to enroll participants; the trial was created on May 29th 2020 and most recently updated November 29 2021 with a goal of recruiting 36 patients from one location."

Answered by AI

What medical condition can Brentuximab Vedotin be used to alleviate?

"Brentuximab Vedotin is the preferred chemotherapy for Hodgkin's disease, but it can also be used to treat systemic anaplastic large cell lymphoma, peripheral T-cell lymphoma and previously untreated conditions."

Answered by AI

Has the FDA sanctioned Brentuximab Vedotin for medical use?

"There is some evidence of safety for brentuximab vedotin, so it was rated a 2 on our scale. Unfortunately, there are no existing studies validating the treatment's efficacy yet."

Answered by AI

How many participants is this research endeavor accommodating?

"Affirmative. According to clinicaltrials.gov, recruitment for this investigation is still open and ongoing; the posting date was May 29th 2020 with a recent edit on November 29 2021. This exploration requires 36 volunteers from one location."

Answered by AI

Is this a groundbreaking clinical trial?

"Presently, there are 59 Brentuximab Vedotin trials in operation across 630 urban areas and 31 nations. Seagen Inc. funded the inaugural study for this drug in 2011 with 79 participants that ultimately secured Phase 2 approval. Subsequently, a further 53 have been conducted to date."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation Antigen 30 (CD30) Positive Peripheral TCell Lymphomas
Marc Hoffmann 2020. "Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation Antigen 30 (CD30) Positive Peripheral TCell Lymphomas". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04334174.
~0 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top